Company: SXTPW
Filing Date: 2025-08-27
Form Type: DEF 14A
Source: 0001213900-25-080878
Chunk: 30

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-08-27
Form: DEF 14A
Chunk 30
---
 of cash compensation paid to our peer group’s independent
directors.

The Compensation Committee has the power and discretion
to determine in the future whether non-employee directors should receive annual or other grants of options to purchase shares of common
stock or other equity incentive awards in such amounts and under such policies as the Compensation Committee may determine utilizing such
market standard metrics as it deems appropriate, including, without limitation, an analysis of equity awards granted to independent directors
of our peer group.

The following table illustrates the compensation
paid by the Company to its directors. The disclosure is provided for the fiscal year ended December 31, 2024.

<div align='center'>Director Compensation

As of December 31, 2024</div>

| Name           |     | Fees Earned or Paid in Cash 
 ($)                         |        |     | Stock  
 Awards 
 ($)    |   |     | Option Awards 
 ($)(1)        |     |     | Non-Equity Incentive Plan Compensation ($) |   |     | All Other Compensation ($) |   |     | Total 
 ($)   |        |
| Charles Allen  |     |                             | 73,000 |     |        | - |     |               | 912 |     |                                            | - |     |                            | - |     |       | 73,912 |
| Cheryl Xu      |     |                             | 65,000 |     |        | - |     |               | 912 |     |                                            | - |     |                            | - |     |       | 65,912 |
| Stephen Toovey |     |                             | 70,000 |     |        | - |     |               | 912 |     |                                            | - |     |                            | - |     |       | 70,912 |
| Paul Field     |     |                             | 70,000 |     |        | - |     |               | 912 |     |                                            | - |     |                            | - |     |       | 70,912 |

| (1) | Represents the aggregate grant date fair value of options granted during the fiscal year, computed in accordance with FASB ASC Topic 718. |

<div align='center'>17

EXECUTIVE COMPENSATION</div>

The following table illustrates the compensation
packages of the Company’s executive officers. The disclosure is provided for the fiscal years ended December 31, 2024 and 2023.
We refer to these individuals as our “